The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessAbstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluentialAntigen-driven bystander suppression after oral administration of antigens.
Miller, A., Lider, O., & Weiner, H. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.791 · Cited by 429 · cited 1×
“Literature on oral tolerance also describes induction of regulatory CD8+ T cells secreting TGF-β cytokine (29).”
BackgroundSnyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394 · cited 1×
“Because of the potential of adenoviral vectors for innate and adaptive immunity and inflammation, it is uncertain whether this vector system can be adapted as a clinical tool for tolerance induction to a therapeutic protein (15, 47).”
BackgroundMount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339 · cited 1×
“Relevance of these data is further supported by results in the null mutation dog model (19).”
ResultSelf-citationKNOLLE, P., SCHMITT, E., JIN, S., GERMANN, T., DUCHMANN, R., HEGENBARTH, S., GERKEN, G., & LOHSE, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70508-1 · Cited by 298 · cited 1×
“Knolle and colleagues have shown that CD4+ T cells primed by liver sinusoidal endothelial cells (LSECs), in contrast to priming by dendritic cells, fail to become Th cells and display a phenotype similar to Th0 cells (34).”
BackgroundA Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B
Lin, H.-F., Maeda, N., Smithies, O., Straight, D. L., & Stafford, D. W. (1997) · Blood · doi:10.1182/blood.v90.10.3962 · Cited by 290
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
Wang, L., Takabe, K., Bidlingmaier, S. M., Ill, C. R., & Verma, I. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3906 · Cited by 222 · cited 2×
“IX transgenes from different viral vectors following intravenous or portal infusion is already well documented in the literature for C57BL/6 mice) (5, 6, 14).”
BackgroundGamma delta T lymphocytes regulate the induction and maintenance of oral tolerance
Ke, Y., Pearce, K., Lake, J. P., Ziegler, H. K., & Kapp, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3610 · Cited by 220 · cited 1×
“Previous work has shown that in mice deficient in T cells expressing the rarer γδ-T cell receptor it is more difficult to induce oral tolerance to antigens (28).”
BackgroundNakai, H., Herzog, R. W., Hagstrom, J. N., Walter, J., Kung, S.-H., Yang, E. Y., Tai, S. J., Iwaki, Y., Kurtzman, G. J., Fisher, K. J., et al. (1998) · Blood · doi:10.1182/blood.v91.12.4600 · Cited by 188
Self-citationHerzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176 · cited 1×
“In contrast, two of two dogs of this colony developed inhibitors within 2 weeks after IM injection of vector (10).”
Self-citationUse of a Liver-Specific Promoter Reduces Immune Response to the Transgene in Adenoviral Vectors
Pastore, L., Morral, N., Zhou, H., Garcia, R., Parks, R. J., Kochanek, S., Graham, F. L., Lee, B., & Beaudet, A. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950017455 · Cited by 170
Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Qian, J., Collins, M., Sharpe, A. H., & Hoyer, L. W. (2000) · Blood · doi:10.1182/blood.v95.4.1324.004k25_1324_1329 · Cited by 168 · cited 1×
“IX formation in protein therapy, as well as in gene therapy, is a Th cell–dependent process (26, 27).”
BackgroundAdeno-associated viral vectors as gene delivery vehicles.
Carter, P. J., & Samulski, R. J. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.6.1.17 · Cited by 157 · cited 1×
“The vector is produced in a helper virus-free system, does not contain viral coding sequences, and is capable of stable in vivo gene transfer (7).”
BackgroundHerzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147 · cited 3×
“IX) vector and in the missense mutation dogs at high vector doses per site of injection (11, 12).”
BackgroundMethodResultSelf-citationNathwani, A. C., Davidoff, A. M., Hanawa, H., Zhou, J., Vanin, E. F., & Nienhuis, A. W. (2001) · Blood · doi:10.1182/blood.v97.5.1258 · Cited by 142
Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, J., Ertl, H. C. J., Herzog, R. W., & High, K. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0032 · Cited by 130
Self-citationHuman Factor IX Corrects the Bleeding Diathesis of Mice With Hemophilia B
Kung, S., Hagstrom, J. N., Cass, D. L., Tai, S. J., Lin, H.-F., Stafford, D. W., & High, K. A. (1998) · Blood · doi:10.1182/blood.v91.3.784 · Cited by 129
Self-citationFields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127 · cited 3×
“IX) vector and in the missense mutation dogs at high vector doses per site of injection (11, 12).”
BackgroundMethodSelf-citationSustained expression of human factor VIII in mice using a parvovirus-based vector
Chao, H., Mao, L., Bruce, A. T., & Walsh, C. (2000) · Blood · doi:10.1182/blood.v95.5.1594.005k34_1594_1599 · Cited by 112
Persistent expression of canine factor IX in hemophilia B canines
Chao, H., Samulski, R. J., Bellinger, D. A., Monahan, P. E., Nichols, T. C., & Walsh, C. E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301024 · Cited by 106
Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy
Connelly, S., Andrews, J. L., Gallo, A., Kayda, D. B., Qian, J., Hoyer, L. W., Kadan, M. J., Gorziglia, M. I., Trapnell, B. C., McClelland, A., et al. (1998) · Blood · doi:10.1182/blood.v91.9.3273 · Cited by 105
Sustained expression of therapeutic levels of human factor VIII in mice
Connelly, S., Gardner, J., Lyons, R., McClelland, A., & Kaleko, M. (1996) · Blood · doi:10.1182/blood.v87.11.4671.bloodjournal87114671 · Cited by 90
Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy
Bagley, J., Tian, C., Sachs, D. H., & Iacomini, J. (2002) · Blood · doi:10.1182/blood.v99.12.4394 · Cited by 74
Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector
Mingozzi, F., Schüttrumpf, J., Arruda, V. R., Liu, Y., Liu, Y.-L., High, K. A., Xiao, W., & Herzog, R. W. (2002) · Journal of Virology · doi:10.1128/jvi.76.20.10497-10502.2002 · Cited by 72 · cited 6×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundMethodSelf-citationHaemophilia B mutations in Sweden: a population‐based study of mutational heterogeneity
Ljung, R., Petrini, P., Tengborn, L., & Sjörin, E. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02759.x · Cited by 71 · cited 1×
“IX genotype of individuals with inhibitor formation is typically characterized by extensive loss of coding information (2).”
BackgroundTran, N., Porada, C. D., Almeida-Porada, G. D., Glimp, H. A., Anderson, W. F., & Zanjani, E. D. (2001) · Blood · doi:10.1182/blood.v97.11.3417 · Cited by 71
Anand, V., Duffy, B., Yang, Z., Dejneka, N. S., Maguire, A. M., & Bennett, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0525 · Cited by 69 · cited 1×
“Second, immune deviation toward IgA/IgG-2b response (as commonly observed in the eye or gut) (30, 31) was seen in only one mouse and was transient.”
BackgroundLe, M., Okuyama, T., Cai, S.-R., Kennedy, S. C., Bowling, W. M., Flye, M. W., & Ponder, K. P. (1997) · Blood · doi:10.1182/blood.v89.4.1254 · Cited by 54 · cited 1×
“IX vector contains four copies of the apolipoprotein E gene enhancer upstream of the human α1-antitrypsin promoter (21), a short chimeric intron, the mF.”
BackgroundInduction of tolerance to human factor VIII in mice
Chao, H., & Walsh, C. (2001) · Blood · doi:10.1182/blood.v97.10.3311 · Cited by 51 · cited 1×
“Besides reports documenting avoidance of immune responses, there are examples of transient neutralizing Ab responses that were downregulated over a period of months (4, 36).”
Background1 The molecular basis of haemophilia A and B
Giannelli, F., & Green, P. M. (1996) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(96)80059-x · Cited by 49 · cited 1×
“Formation of inhibitory Ab’s against the infused coagulation factor currently represents the most serious complication of treatment by conventional protein replacement therapy and occurs in 3–4% of hemophilia B patients (1).”
BackgroundFields, P., Armstrong, E., Hagstrom, J. N., Arruda, V. R., Murphy, M., Farrell, J. P., High, K. A., & Herzog, R. W. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301409 · Cited by 43 · cited 3×
“Because of the potential of adenoviral vectors for innate and adaptive immunity and inflammation, it is uncertain whether this vector system can be adapted as a clinical tool for tolerance induction to a therapeutic protein (15, 47).”
BackgroundMethodResultSelf-citationBristol, J. A., Gallo-Penn, A. M., Andrews, J., Idamakanti, N., Kaleko, M., & Connelly, S. (2001) · Human Gene Therapy · doi:10.1089/10430340152528147 · Cited by 27 · cited 1×
“VIII formation with a low-expressing AAV vector after hepatic gene transfer (45, 46).”
BackgroundVemuru, R. P., Davidson, A., Aragona, E., Chowdhury, J. R., Burk, R. D., & Gupta, S. K. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.10.1634046 · Cited by 26 · cited 1×
“The liver has been implicated in oral and in portal venous tolerance (40, 41).”
BackgroundGeorgantas, R. W., Leong, K. W., & August, J. T. (2000) · Human Gene Therapy · doi:10.1089/10430340050015464 · Cited by 22
Cabo II: Immunology and Gene Therapy
(2002) · Molecular Therapy · doi:10.1006/mthe.2002.0595 · Cited by 6
Research works printed but not linked: 2
- Carter, 2000, Int. J. Mol. Med., 6, 17
- Nakai, 2000, Blood., 96(Suppl.), 798a
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Mátés, L., Chuah, M. K. L., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, A., Grzela, D. P., Schmitt, A., Becker, K., Matrai, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.343 · Cited by 948
“This suggests that hepatic expression of FIX following nonviral transposon-mediated gene delivery may be associated with the induction of FIX-specific immune tolerance [13].”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“Subsequent work demonstrated that expression of a transgene from an AAV vector in the liver promotes tolerance to the transgene produc”
BackgroundSelf-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“While in preclinical settings, AAV-mediated transgene expression in the liver is reproducibly achieved using both constitutive and tissue-specific promoters; the restriction of transgene expression in hepatocytes is a preferred choice to avoid the expression of the transgene product in antigen-presenting cells (that m…”
BackgroundSelf-citation
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.